Abilify
Lundbeck gets go-ahead for US and EU licence expansions
February 4, 2016Medical Communications, Sales and Marketing Abilify, EMA, FDA, Lundbeck, Otsuka, Takeda, aripiprazole, brintellix, vortioxetine
Lundbeck has earned two recommendations from regulatory committees of the FDA and the EMA, which both recommended the company’s drugs …
Otsuka buys Avanir for $3.5 billion
December 3, 2014Sales and Marketing Abilify, Alzheimer's, Alzheimer’s, Nuedexta, Otsuka, Parkinson's, Parkinson’s, avanir
Otsuka is to buy Avanir Pharmaceuticals for $3.5 billion as it looks to make up for the imminent patent expiry …
Alkermes schizophrenia drug shines in Phase III
April 8, 2014Medical Communications, Research and Development, Sales and Marketing Abilify, Alkermes, aripiprazole, schizophrenia
Alkermes’ investigational schizophrenia drug has met its primary endpoint in a pivotal trial, leading the firm to seek regulatory approval …
NICE thumbs-up for Abilify
June 7, 2013Sales and Marketing Abilify, BMS, NICE, Otsuka
Adolescents who suffer from bipolar disorder should be treated on the NHS with Otsuka Pharmaceuticals’ Abilify, according to draft guidance …
Lundbeck and Otsuka to collaborate in CNS
November 11, 2011Research and Development, Sales and Marketing Abilify, CNS, Lundbeck, Otsuka
Lundbeck and Otsuka have signed a major collaborative deal to sell and develop up to five CNS drugs, including a …
NICE decides to back Abilify in schizophrenia
January 27, 2011Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia
NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …
NICE won’t approve Abilify without more data
September 13, 2010Sales and Marketing Abilify, BMS, NICE
NICE is unlikely to approve Bristol-Myers Squibb’s schizophrenia drug Abilify unless the company can provide more data on its clinical …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
